Activating mutations in RAS and receptor tyrosine kinases such as KIT and FLT3 are hypothesized to cooperate with chimeric transcription factors in the pathogenesis of acute myeloid leukemia (AML). To test this hypothesis, we genotyped 150 pediatric AML samples for mutations in KIT (exons 8, 17), NRAS and KRAS (exons 1, 2) and FLT3/ITD. This is the largest cohort of pediatric AML patients reported thus far screened for all four mutations. Of the children with AML, 40% had a mutation in KIT (11.3%), RAS (18%) or FLT3/ITD (11.1%), and 70% of cases of core-binding factor (CBF) leukemia were associated with a mutation of KIT or RAS. Mutations in RAS or FLT3/ITD were frequently found in association with a normal karyotype. Patients with a FLT3/ITD mutation had a significantly worse clinical outcome. However, the presence of a KIT or RAS mutation did not significantly influence clinical outcome. We demonstrate that KIT exon 8 mutations result in constitutive ligand-independent kinase activation that can be inhibited by clinically relevant concentrations of imatinib. Our results demonstrate that abnormalities of signal transduction pathways are frequent in pediatric AML. Future clinical studies are needed to determine whether selective targeting of these abnormalities will improve treatment results.
Introduction
The prognosis of pediatric acute myeloid leukemia (AML) has improved considerably over the past decades, with overall long-term survival rates around 60%. [1] [2] [3] [4] However, relapse remains the major cause of treatment failure, occurring in 30-40% of patients in first complete remission (CR). [1] [2] [3] [4] Several study groups have shown that cytogenetics is an independent and strong predictor of outcome, both in childhood and adult AML. 2, 3, 5 It is hypothesized that AML results from two classes of cooperating mutations. [6] [7] [8] Type II mutations affect hematopoietic stem cell differentiation, typically by mutations or translocations (eg t(8;21), t (15;17) or inv (16) ), resulting in aberrant function of transcription factor complexes. However, these mutations alone are insufficient to induce leukemia. 9 Patients with core-binding factor (CBF) leukemias, that is, t(8;21) (AML1-ETO) and inv (16) (CBFb-MYH11) have a better prognosis than patients with normal cytogenetics or non-CBF cytogenetic abnormalities, with overall survival (OR) rates of 70-80%. 3, 5 Normally, AML1 and CBFb are part of the CBF complex, a DNA-binding transcription factor complex. Together with other factors the CBF complex regulates the transcription of many genes important for the differentiation of hematopoietic cells. 10 In pediatric AML approximately 15% of patients have t (8;21) and approximately 10% of patients have an inv (16) , for an overall incidence of CBF leukemia of 20-30% in pediatric AML patients. 5 Type I mutations provide a proliferative and survival advantage to hematopoietic progenitors. 9 This group includes activating mutations in receptor tyrosine kinases (RTKs) such as FLT3 and KIT and the GTPase RAS.
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KIT receptor is a member of the type III receptor tyrosine kinase family, that also includes FLT3 and PDGFRs. 15 Activating mutations in KIT were first described in the mast cell leukemia cell line HMC-1 and activating mutations in KIT have subsequently been identified in AML, mastocytosis, gastro-intestinal stromal tumor (GIST) and seminoma/dysgerminoma. [16] [17] [18] [19] Functional studies demonstrated that these KIT mutations conferred cytokine-independent survival and a growth advantage to cells. 11 The RAS family of genes consists of three G-proteins, NRAS, KRAS and HRAS. 20 The RAS proteins are important in relaying proliferation and survival signals from cell membrane receptors (including KIT and FLT3) to intracellular signal transduction pathways. Certain mutations in RAS induce a permanent activation of RAS. Mutations in NRAS or KRAS have been identified in numerous malignancies, including hematologic malignancies such as AML. [20] [21] [22] We genotyped 150 pediatric AML samples for mutations in KIT (exons 8 and 17), NRAS (exons 1 and 2) and KRAS (exons 1 and 2). In addition, the 27 CBF AML samples were genotyped for KIT exons 9 and 11 mutations, which were recently described in t(8;21) positive AML. 23 This same cohort of patients was previously tested for FLT3/ITD. 24 This is the largest cohort of pediatric AML patients to date that has been screened for mutations in all four genes. 40% of children with AML had a mutation in KIT (11.3%), RAS (18%) or FLT3/ITD (11.1%). Mutations in KIT and RAS were predominantly found in CBF leukemia, in which 70% of cases had one of these mutations. Mutations in RAS and FLT3/ITD occurred in 50% of samples from patients with normal cytogenetics. In contrast to FLT3/ITD, KIT or RAS mutations did not influence clinical outcome. In addition, we provide biochemical evidence that KIT exon 8 mutations result in constitutive activation of KIT kinase activity that can be inhibited by clinically relevant concentrations of imatinib mesylate.
Materials and methods

Patient samples
Stored cytospin slides of bone marrow or peripheral blood samples from 183 pediatric (0-p18 years of age) AML patients were available for analysis. Samples were only taken after informed consent had been obtained and with Institutional Review Board (IRB) approval. We excluded patients with secondary AML (n ¼ 11), mixed lineage leukemia (n ¼ 2), refractory anemia with excess of blasts transformation (RAEB-T) (n ¼ 2), AML after myelodysplastic syndrome (n ¼ 8) and Down's syndrome AML (n ¼ 8). Two patients were not treated with curative intent and were also excluded. Thus, the study population described here consists of 150 de novo pediatric AML patients.
Two collaborative groups participated in this study: the AML-'Berlin-Frankfurt-Mü nster' Study Group (AML-BFM-SG, Mü nster, Germany) and the Dutch Childhood Oncology Group (DCOG, The Hague, the Netherlands). Both study groups performed central review of the diagnosis, classification and clinical follow-up of the patients.
All patients were reclassified according to the BFM-AML risk group classification criteria. 'Standard risk' (SR) patients were defined as having favorable morphology (ie French-AmericanBritish (FAB) M2 with Auer rods, M3 or M4 with eosinophils) and blast cell reduction in the bone marrow on day 15 to o5% (not obligatory for FAB M3). All other patients were considered 'high risk' (HR). 25 
Treatment protocols
Patients were all treated on intensive cytarabine/anthracyclines based protocols in the Netherlands and Germany in the period from 02-1990 until 02-2000 (protocols DCOG AML 87, 94 and 97 and AML-BFM 93 and 98). The treatment protocols have been reported in detail elsewhere. 1, 3, [25] [26] [27] In the AML BFM 93 study, the patients were stratified according to risk groups. At diagnosis, patients were randomized between daunorubicin (plus cytarabine and etoposide, ADE) and idarubicin (plus cytarabine and etoposide, AIE) induction therapy, which did not result in differences in longterm outcome. 1 For HR patients, one of the intensification blocks was changed to high-dose cytarabine with mitoxantrone (HAM), which improved treatment outcome compared with protocol AML BFM 87. 1 Sibling SCT was advised for HR patients in first CR. SR patients did not receive HAM and outcome was identical to the AML BFM 87 study. Protocol AML BFM 98 consisted of induction with the idarubicin block, followed by HAM. In the consolidation phase patients were randomized for either receiving the 6-week consolidation block followed by one intensification block, vs three intensive courses of chemotherapy.
The DCOG AML 87 and 94 protocols were based on the concurrent AML-BFM protocols. In brief, the DCOG AML 87 protocol started with an 8-day induction course, followed by a 6-week consolidation block. Then two intensification courses were given. Intrathecal chemotherapy was given as central nervous system (CNS) prophylaxis. Contrary to the AML BFM 87 study, no maintenance therapy was given. Sibling donor allogeneic stem cell transplantation (SCT) was advised for high-risk patients in first CR. In protocol DCOG AML 94 all patients received the idarubicin arm in induction, as well as the HAM block for consolidation. No maintenance therapy was given. Patients were transplanted with either an HLA-identical sibling donor or autograft. Patients enrolled in DCOG AML 97, which was identical to the Medical Research Council's AML12 protocol, were stratified according to cytogenetics. Good risk patients (defined as patients with t(8;21), inv (16) or t(15;17)) were not eligible for SCT. Patients were randomized to induction treatment with either ADE (cytarabine, daunorubicin and etoposide) or MAE (mitoxantrone, cytarabine and etoposide), followed by 4 or 5 (randomized) treatment courses. The fifth extra course was high-dose cytarabine and asparaginase. If a matched sibling donor was available, SCT was recommended as the fourth or fifth course (randomized).
Mutation detection
Low-density mononuclear cell populations of bone marrow or peripheral blood were isolated after density gradient centrifugation of the sample using Ficoll Isopaque. Cytospin slides were prepared and stored at À201C. The cytospin slides used, contained a median of 88% of blasts (p25-p75: 81-92%). After thawing, genomic DNA was extracted by rehydrating the slides and purifying the DNA using the QiaAmp DNA Mini Kit (Qiagen, Valencia, CA, USA).
For KIT, NRAS and KRAS mutation detection the purified DNA was subjected to 45 cycles of polymerase chain reaction (PCR) using the High-Fidelity PCR System (no. 1732078; Roche, Basel, Switzerland). A nested PCR was performed in cases of low amplification yield. 28, 29 The primers sets used are available online as Supplementary Information at www.nature.com/leu. For nested PCR, 1 ml of the initial PCR reaction was used as template for the nested PCR and amplified for additional 25 cycles. Negative controls were included in every set of amplifications. For nested PCR reactions, 1 ml of the negative control (water only) from the first stage PCR was amplified as an additional negative control. Aliquots of the final PCR reaction were screened for mutations on a Transgenomic WAVE HPLC system (D-HPLC; Transgenomic, Inc., Omaha, NE, USA) by running an HPLC under nondenaturing conditions and partially denaturing conditions. D-HPLC-detected mutations were confirmed by two methods: (1) reamplification of the exon and repeat D-HPLC analysis on a different day and (2) bi-directional sequence analysis on an ABI 377 sequencer using the BigDye terminator kit (Applied Biosystems, Inc., Foster City, CA, USA).
We previously genotyped 144 patients in the study population for a FLT3/ITD and 11.1% (n ¼ 16) had a FLT3/ITD.
Western blot analysis of KIT exon 8 mutant isoform
The KIT exon 8 mutation TYD 417-419I was generated by sitedirected mutagenesis of wild-type KIT cDNA that had been cloned into pcDNA3.1 (Invitrogen Corp., Carlsbad, CA, USA). This mutation was originally described by Gari et al 17 and is similar to the TYD417-419RA mutation seen in one patient in the current series. Chinese Hamster Ovary (CHO) cells were transiently transfected with pcDNA3.1 encoding wild-type or exon 8 mutant KIT cDNA. At 24 h after transfection, the cells were stimulated for 10 min with 100 ng/ml of KIT ligand (KIT LG) or vehicle control. In addition, 24 h after transfection, cells were treated with imatinib mesylate in increasing concentrations or vehicle control, as previously described. 30 Following treatment, protein lysates were prepared and immunoprecipitated with a specific anti-KIT polyclonal antiserum (sc#168, Santa Cruz Biotechnologies, Santa Cruz, CA, USA). The immunoprecipitated proteins were sequentially immunoblotted using an anti-phosphotyrosine monoclonal antibody (P-KIT) (#610 000, BD transduction laboratories, San Jose, CA, USA) and followed by an anti-KIT polyclonal antiserum (KIT) (PC-34, Oncogene research, Callbiochem, San Diego, CA, USA). The imatinib was generously provided by Dr Elisabeth Buchdunger (Norartis Pharma, AG, Basel, Switzerland).
Statistical analysis
To assess the outcome, the following parameters were used: CR rate, event-free survival (EFS), disease-free survival (DFS), OS and cumulative incidence of relapses. CR was defined as less than 5% leukemic cells in a bone marrow aspirate, no evidence of leukemia at any other site and hematological recovery, according to CALGB criteria. 31 Early death was defined as death within the first 6 weeks of treatment. EFS was defined as the time from diagnosis until the date of first adverse event (relapse, death of any reason or secondary malignancy), or in case no events occurred, until the date of last follow-up. Patients who did not attain a CR were considered failures at time-point zero. DFS was defined as time from CR until date of first relapse or, if no relapse occurred, until the date of last follow-up. OS was defined as the time from diagnosis until death of any cause or last follow-up. Probabilities of EFS (pEFS) and OS (pOS) were estimated by the methods of Kaplan and Meier with standard errors according to Greenwood, and were compared using the log-rank test. The cumulative incidence functions of relapse were constructed by the method of Kalbfleisch and Prentice for patients who achieved a CR and compared with Gray's test.
For statistical comparison of categorical values the w 2 test was used. Fisher's exact test was used when data were sparse. To assess differences in the distribution of continuous data, the nonparametric Mann-Whitney U-test was used. P-values of p0.05 were considered statistically significant (two-tailed test).
Results
Patient characteristics
We successfully evaluated 150 de novo pediatric AML patients for the incidence and prognostic significance of mutations of KIT (exons 8 and 17), NRAS and KRAS (both exons 1 and 2). In addition, the CBF AML samples included in this study were genotyped for KIT exons 9 and 11 mutations. These 150 patients include 91 of the 748 (12%) de novo childhood AML patients included in the AML-BFM SG trials and 59 of the 120 (49%) de novo AML patients included in the DCOG trials in the abovementioned period. Detailed patient characteristics are available online as Supplementary Information at www.nature.com/leu. According to the BFM criteria, 56 patients (37%) were SR, and 94 HR (63%), consistent with the distribution in the entire population of patients in the AML-BFM studies. The study population was compared to the AML-BFM study group patients included in this time period and were shown to differ only in a higher WBC count at presentation (27.3 vs 19.4 Â 10 9 /l, P ¼ 0.027), but no significant differences in age or sex were found. Outcome was comparable in the study population and the overall AML-BFM population (pEFS 44 vs 46%, P ¼ 0.94). Cytogenetic information of 118 patients (79%) was available. Of these 118 patients, 27 (23%) had CBF AML, 16 had t(8;21) (13.6%) and 11 inv(16) (9.3%).
KIT mutations
Overall, 17 of the 150 patients (11.3%) had a mutation in either KIT exon 8 (6 patients, 4%) or exon 17 (11 patients, 7.3%) ( Table 1 ). There were no differences in age (P ¼ 0.52), WBC at diagnosis (P ¼ 0.45) or sex distribution (P ¼ 0.61) between patients with and patients without KIT mutations. None of the 27 CBF AML samples harbored a KIT exon 9 or 11 mutation. All the mutations of KIT exon 17 involved residues in the KIT activation loop and have been previously shown to result in constitutive kinase activity. 11, 16 The most commonly affected residue was codon 816 (D816Y or D816V). Less commonly, we found mutations encoding for substitutions at codons 822 (N822K) and Y823 (Y823D). None of the KIT mutated patients also had an FLT3/ITD. AML-associated genomic alterations of KIT exon 8 encode for constitutively active, imatinib-sensitive kinases
The KIT exon 8 mutations all consisted of in-frame deletions that were usually accompanied by insertion of additional nucleotides, consistent with a previous report. 17 All mutations resulted in loss of the aspartic acid residue at amino acid 419 located in the KIT extracellular domain. 17 It has been hypothesized that AML-associated KIT exon 8 mutations result in ligand-independent activation of KIT kinase activity, similar to the extracellular KIT exon 9 mutations seen in GISTs. 30 To determine the biochemical properties of these mutations we transiently expressed the exon 8 mutant KIT TYD417-419I in CHO cells and performed Western blot analysis. Cells expressing mutant KIT showed constitutive ligand-independent KIT autophosphosphorylation, thus proving that AML-associated KIT alterations of exon 8 are indeed gain-of-function mutations (Figure 1a ). In addition, this constitutive autophosphorylation was potently inhibited by imatinib in a dose-dependent manner, with an IC 50 of approximately 200-300 nM (Figure 1b) .
RAS mutations
Of pediatric AML patients, 18% (n ¼ 27) (Figure 2a ) had an activating mutation of either NRAS exon 1 (n ¼ 16, 10.7%), 
KIT and RAS mutations in cytogenetic subgroups
A total of 27 patients in this study were confirmed to have CBF AML, with 16 patients having t(8;21) and 11 with inv(16). In this group of patients, 10 (37%) had a KIT mutation, eight (29.6%) had a mutation in NRAS or KRAS and one patient (3.7%) had an FLT3/ITD mutation (Figure 2a) . One patient had a mutation in both KIT exon 8 and NRAS exon 2. Thus, in 70% of pediatric CBF AML patients we found a type I mutation, compared to only 32.5% in non-CBF AML patients (Po0.0001). The incidence of KIT mutations in the inv(16) group was 54.5% (27.2% for exon 8 and 27.2% for exon 17). In t(8;21) positive patients the incidence of KIT exons 8 and 17 mutations was 31.3% (12.5% exon 8, 18.8% exon 17). The incidence of RAS mutations in the inv(16) and t(8;21) subgroups was 25% and 36.4%, respectively. A total of 30 patients in the studied cohort had normal cytogenetics, with 57% of these patients having a mutation in either RAS (30%) or KIT (6.7%) or FLT3/ITD (20%), compared to only 35% in all other patients (P ¼ 0.030). One patient with a KIT mutation and six patients with a RAS mutation had no available cytogenetic studies.
KIT and RAS mutations in FAB subgroups
The three most prevalent FAB types in the patient cohort were M2 (26%), M4 (28%) and M5 (21%). When examining these three subgroups, it was clear that in M2 (48.7%) and M4 (54.8%) RAS, KIT or FLT3/ITD mutations were frequent, while in FAB M5 only 19% of patients had a mutation of RAS (9.7%), KIT (6.5%) or FLT3/ITD (3.2%) (Figure 2b ). FAB-type M2/M4 was found in 82% of patients with KIT mutations compared to 45% in patients without mutations (P ¼ 0.027). FAB-types M2 and M4 were also overrepresented in the patients with RAS mutations (74% of mutated vs 50% of wild-type RAS samples, P ¼ 0.021).
Clinical outcome and prognostic significance of RAS and KIT mutations and FLT3/ITD There were no significant differences in 5-year pEFS (45% in both, P ¼ 0.77), 5-year pOS (60 vs 56%, P ¼ 0.40) and cumulative incidence of relapses (44 vs 36%, P ¼ 0.62) between KIT-mutated and non-mutated patients. In addition, there were no significant differences in 5-year pEFS (59 vs 41%, P ¼ 0.25) Figure 1 (a) Constitutive kinase activation of KIT exon 8 mutant isoform. CHO cells were transiently transfected with an expression vector encoding cDNAs for either wild-type KIT (KITWT) or a KIT exon 8 mutant isoform (TYD417-419I). Transfected cells were treated with vehicle or KITLG. KIT protein was immunoprecipitated and immunoblotted for phosphoKIT (P-KIT) and total KIT (KIT) as described above. The activation of wild-type KIT is almost entirely ligand dependent, whereas the KIT exon 8 mutant protein is constitutively phosphorylated with little change following ligand treatment. The arrows indicate the location of the completely (top arrow) and incompletely glycosylated forms of KIT. The vast majority of the wild-type protein is completely glycosylated and phosphorylation is largely confined to this isoform. In contrast, the majority of the KIT exon 8 mutant protein is incompletely glycosylated, and only this isoform undergoes any significant degree of tyrosylphosphorylation. (b) The kinase activity of the KIT exon 8 mutant isoform is sensitive to imatinib in vitro. CHO cells were transiently transfected with an expression vector encoding a KIT exon 8 mutant isoform (TYD417-419I). KIT protein was immunoprecipitated as described above and immunoblotted for phosphoKIT (P-KIT) and total KIT (KIT) as described above. The autophosphorylation of the KIT exon 8 mutant isoform is potently inhibited by imatinib with an in vitro IC 50 of approximately 200-300 nM.
Figure 2
Relationship between cytogenetics and FAB type and mutations in RAS, KIT and FLT3/ITD in 150 newly diagnosed pediatric AML patients. Overall, we found a mutation in RAS or KIT or FLT3/ITD in 40% of patients. (a) In patients with normal cytogenetics this was 57% compared to 70% in patients with CBF AML. Of inv(16) positive patients, 81.8% had either a RAS or KIT mutation or an FLT3/ITD compared to 62.5% in t(8;21) positive patients. Mutations in RAS, KIT and FLT3/ITD were rare in patients with 11q23 (MLL) abnormalities (18.2%), t(15;17) and patients with all other cytogenetic abnormalities (19.4%). (b) In patients with FAB-types M2 and M4 we found a RAS or KIT mutation or FLT3/ITD in 48.7% and 54.8%, respectively. This was only 19.4% in patients with FAB-type M5. Patients with FAB-type M1 had a mutation in RAS or FLT3/ITD in 31% of cases.
and 5-year pOS (67 vs 54%, P ¼ 0.35) between patients with and without RAS mutations. However, patients with RAS mutations were less likely to relapse than patients without such mutations (22 vs 45% cumulative incidence of relapses, P ¼ 0.08). When the 5-year pEFS for all four subgroups (no mutation, KIT mutation, RAS mutation and FLT3/ITD) were compared (Figure 3a) , patients with FLT3/ITD had a significantly worse outcome (5-year pEFS FLT3/ITD vs no mutation, 9 vs 47%, P ¼ 0.0001). The differences between all other subgroups were not significant. Patients with RAS mutations had the lowest cumulative incidence of relapses of all four groups, but the difference was not statistically significant (23 vs 42% in the nonmutated group, P ¼ 0.17) (Figure 3b) . Of the patients, 27% received an SCT in first CR. Overall, there was no significant impact of SCT on DFS (relative risk (RR) 1.07, P ¼ 0.88) or OS (RR 1.08, P ¼ 0.81) in this cohort of patients. Multivariate analysis of DFS was performed, including as variables BFM risk group, WBC450.0 Â 10 9 /l, SCT in CR1, KIT, RAS and FLT3/ITD. The only variables significantly related to outcome were the presence of an FLT3/ITD (DFS RR ¼ 2.49, P ¼ 0.003) and BFM risk group (RR ¼ 1.94, P ¼ 0.008). SCT in CR1 (RR ¼ 0.96, P ¼ 0.89), mutated KIT (RR ¼ 1.07, P ¼ 0.86) and mutated RAS (RR ¼ 0.75, P ¼ 0.41) did not influence DFS in multivariate analysis. Within the CBF AML subgroup (n ¼ 27) there was no significant difference in pEFS between patients with and without a KIT mutation (pEFS ¼ 49% (s.e. 16%) vs 63% (s.e. 12%), P ¼ 0.64). RAS mutational status also did not significantly influence pEFS in the CBF AML subgroup (mutated RAS pEFS ¼ 75% (s.e. 15%) vs wild-type RAS pEFS ¼ 50% (s.e. 12%), P ¼ 0.32).
Discussion
In this study, we examined the incidence and prognostic significance of KIT and RAS mutations in a large cohort of 150 pediatric AML patients. The same cohort of patients was previously characterized for FLT3/ITD. 24 This is the largest cohort of pediatric AML patients reported that has been genotyped for KIT, NRAS, KRAS and FLT3/ITD mutations. Overall, we found a mutation in either KIT (11.3%), RAS (18%) or a FLT3/ITD (11.1%) in 40% of pediatric AML patients. This is the first report of an AML-associated activating mutation of KIT codon Y823. However, this activating mutation has previously been reported in seminoma. 19 The incidence of KIT mutations has mainly been studied in adult AML with a reported 1.3% incidence of exon 17 mutations in a large cohort of unselected adult AML patients (n ¼ 1114). (Schnittger S et al. Blood 2002; 100(11): 196a; abstract) The reported incidence in adult AML with inv(16) ranges from 10 to 33% and from 9-48% in t(8;21) positive adult AML. 23, 32, 33 (Bö ll I et al. Blood 2002; 100(11): 746a; abstract) The pediatric AML literature on KIT mutations is sparse. One study reported on one child with a KIT mutation in a group of 15 patients with CBF AML. 32 In another study, only one out of 27 pediatric patients (3.7%) had a KIT exon 17 mutation. 34 Recently, Meshinchi et al 35 reported KIT exon 17 mutations in 3/91 patients (3.3%) with pediatric AML. Thus, the incidence of exon 17 mutations in our study (7.3%) is considerably higher than the incidence reported in the literature.
Mutations of NRAS or KRAS are found in 13-20% of cases of adult AML. 18, 19, 36, 37 RAS mutations in pediatric AML have been previously reported, albeit, in smaller cohorts of patients (10-99 patients), with frequencies of 6-37%. 35, [38] [39] [40] [41] [42] In most studies NRAS mutations were more frequent than KRAS mutations, in agreement with our own study in which 14.7% of patients had a NRAS mutation and only 3.3% a KRAS mutation.
When we examined different subgroups, it was clear that there were nonrandom relations between the different mutations and certain cytogenetic subgroups. In 70% of CBF AML patients a mutation in either RAS (26%), KIT (37%), KIT and RAS (3.7%), or an FLT3/ITD (3.7%) was detected. FLT3/ITD was not seen in inv (16) and was seen in only one patient with t(8;21). In the normal cytogenetics subgroup FLT3/ITD (20%) and RAS (30%) mutations were frequent, while KIT mutations were rare (6.6%). Notably, in our series KIT mutations were as frequent as FLT3/ ITD mutations. This distribution of mutations is markedly different from adult AML where FLT3 mutations are relatively common (15-30% of patients), whereas KIT mutations are Figure 3 (a) The 5-year probability of event-free survival in patients with RAS and KIT mutations, FLT3/ITD and patients without known type I mutations. The 5-year pEFS in RAS-mutated patients was 58% (s.e. 10%), in patients without mutations 47% (s.e. 6%), in KITmutated patients 43% (s.e. 13%) and 9% (s.e. 8%) in patients with FLT3/ITD. The 5-year pEFS was significantly lower in FLT3/ITD positive patients compared to all other subgroups (FLT3/ITD vs nonmutated patients P ¼ 0.0001). (b) The 5-Year cumulative incidence of relapses in patients with RAS and KIT mutations, FLT3/ITD and patients without mutations. The 5-Year cumulative incidence of relapses in RAS-mutated patients was 23% (s.e. 10%), in patients without mutations 42% (s.e. 6%), in KIT-mutated patients 49% (s.e. 15%) and 65% (s.e. 29%) in FLT3/ITD positive patients. There were no significant differences between patients without mutations and RAS (P ¼ 0.17), KIT (P ¼ 0.71) and FLT3/ITD (P ¼ 0.10)-mutated patients.
rare. 32, 33, 43 5 These nonrandom relations between type I mutations and type II mutations provide support for the hypothesis that these two type of mutations cooperate in causing AML. 6 Data supporting this hypothesis have also come from mouse models in which type I and type II mutations were induced in stem cells and the mice developed AML-like disease; however, the two types of mutations expressed in isolation do not induce a leukemic phenotype. [6] [7] [8] [9] A prediction of this model is that the different mutations that induce proliferation should be mutually exclusive as only one mutation would be required for leukemogenesis. Our data support this prediction as the three groups of mutations in general were mutually exclusive. The non-random association of KIT or RAS mutations in patients with CBF leukemia suggests that there may be a requirement for certain signaling events for efficient leukemogenesis in the setting of aberrant genetic programming induced by these fusion transcription factors. Conversely, FLT3 mutations seem to be much more efficient in inducing proliferation of leukemic stem/ progenitor cells with t(15;17) whereas KIT or RAS mutations are much less efficient and are rarely found in association with APL. 43 Overall, we were able to detect a type I mutation in 40% of our patients, suggesting that other type I mutations contribute to leukemogenesis. Notably, 81% of patients with FAB M5 AML had no detectable mutation of KIT, RAS or FLT3/ITD. In the current report we have genotyped for four different type I mutations, but of course there are many more possibilities, both known (such as other mutations of FLT3 or PTPN11 mutations) and unknown.
We also studied the prognostic impact of KIT and RAS mutations in pediatric AML. Some studies have reported that KIT or RAS mutations confer a poor prognosis. 28, 35, 37, 44, 45 In this cohort of patients we were unable to demonstrate any significant a prognostic impact of RAS or KIT mutations, although this may be due to the fact that treatment was heterogeneous. The lack of a prognostic impact of KIT or RAS mutations is in marked contrast to the strong negative impact of FLT3/ITD mutations in our study population. 24 However, we cannot rule out the possibility that RAS and KIT mutations do have prognostic impact, albeit less strongly than FLT3/ITD mutations. As RAS and KIT mutations are particularly frequent in the CBF subgroup, we also analyzed outcome in this subgroup of AML patients, but no differences in outcome were detected. Interpretation of the analysis of outcome in this subgroup is limited by the heterogeneous treatment the patients received and the small number of CBF AML patients included in this study. Further studies should focus on the prognostic impact of RAS and KIT mutations in a large prospective cohort of pediatric CBF AML patients.
This study demonstrates that KIT exon 8 mutations are legitimate gain-of-function mutations, resulting in ligand-independent constitutive activation of KIT (as assessed by autophosphorylation). In addition, we were able to show that this autophosphorylation could be potently inhibited in a dosedependent fashion by the tyrosine kinase inhibitor imatinib mesylate with an IC 50 of 200-300 nM, which is comparable to the IC 50 found for wild-type KIT. 46 Overall, 59% of the KIT mutations found in our study are sensitive to imatinib in vitro. Recently, two papers also addressed the biochemical properties of exon 8 mutated KIT. 47, 48 Both show that exon 8 mutant KIT induces ligand independence. In addition, Growney et al 47 show that PKC412 can inhibit autophosphorylation in all tested KIT mutants, including the imatinib-resistant D816 mutants.
An important aspect of the current study is the ongoing clinical development of small molecule inhibitors. Tyrosine kinase inhibitors could have clinical potential in the treatment of pediatric AML with FLT3 or KIT mutations. In addition, drugs targeting activated RAS could potentially be effective in AML cases with mutated RAS or activating mutations in signaling proteins upstream of RAS. Future clinical studies are needed to test the hypothesis that the use of small molecule inhibitors would improve the prognosis of children with KIT, RAS or FLT3/ ITD mutations.
